Document is current
Any future updates will be listed below
-
Authors
Gelineau, Nina U.
Bozsaky, Eva
van Zogchel, Lieke M. J.
Rifatbegovic, Fikret
Lazic, Daria
Ziegler, Andrea
Javadi, Ahmad
Zappeij-Kannegieter, Lily
Pötschger, Ulrike
Fiocco, Marta
Ambros, Peter F.
Ambros, Inge M.
Bodenmiller, Bernd
van der Schoot, Ellen C.
Ladenstein, Ruth
Bernkopf, Marie
Tytgat, Godelieve A. M.
Taschner-Mandl, Sabine
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (TRANSCAN 8352/TRS-2018-00000715)
Austrian Science Fund (https://doi.org/10.55776/I4162)
- License Information
-
More Information
Article History
Received: 29 March 2025
Accepted: 15 July 2025
First Online: 2 August 2025
Declarations
:
: Bone marrow samples were taken from patients treated within the international SIOPEN/HR-NBL1 trial (NCT01704716) [, ] or the Dutch DCOG NB2009 trial (NCT01704716) []. The study was approved by the Medical Research Ethics Committee of the Academic Medical Center (Amsterdam, the Netherlands; MEC07/219#08.17.0836) and the Ethics Committee of the Medical University of Vienna (Vienna, Austria; EK#1853/2016, EK#1216/2018). It was conducted according to the Declaration of Helsinki, with written informed consent obtained from parents or guardians [].
: Not applicable.
: The authors declare no competing interests.
